

**Agenda**  
**Prevention of group A streptococcal diseases and their sequelae**  
**with a focus on vaccine related issues**  
**Fernwood Building, Bethesda, MD**  
**March 29 and 30, 2004**

**March 29, 2004**

<b>8:30-8:45</b>	<b>Welcome and introductions Goal of the workshop</b>	<b>Fran Rubin</b>
<b>8:45-9:10</b>	<b>Overview historical view of vaccine development</b>	<b>Alan Bisno</b>
<b>9:10-10:10</b>	<b>Epidemiology/ Burden of Disease</b>	<b>Jonathan Carapetis Anne Schuchat</b>
<b>10:10-10:30</b>	<b>Break</b>	
<b>10:30-12:00</b>	<b>Immunology/pathogenesis considerations for vaccine development including animal models</b>	<b>Madeleine Cunningham Malak Kotb</b>
<b>12:00-1:00</b>	<b>Lunch</b>	
<b>1:00-2:00</b>	<b>Immune correlates including laboratory considerations (serological assays)</b>	<b>Pat Cleary Jim Dale</b>
<b>2:00-3:20</b>	<b>Vaccine clinical trial design</b>	<b>Karen Kotloff Kate O' Brien</b>
<b>3:20-3:40</b>	<b>Break</b>	
<b>3:40-4:20</b>	<b>Perspective from industry</b>	<b>4 presentations</b>
<b>4:20-5:30</b>	<b>FDA considerations for vaccine development</b>	<b>Marion Gruber Chris Mink Norman Baylor</b>

**March 30, 2004**

<b>8:00-9:45</b>	<b>Implementation: US, Global, Economics</b>	<b>Jeff Davis Thomas Cherian Amie Batson</b>
<b>9:45-10:00</b>	<b>Break</b>	
<b>10:00-10:30</b>	<b>Identification of obstacles for vaccine development and gaps in knowledge</b>	<b>Sam Katz</b>
<b>10:45-12:30</b>	<b>Break out sessions</b>	
<b>12:30-1:30</b>	<b>LUNCH</b>	
<b>1:30-2:50</b>	<b>Recommendations/Discussion Breakout groups</b>	<b>Sam Katz Stan Shulman</b>
<b>2:50-3:20</b>	<b>Next steps moving forward</b>	<b>Orin Levine</b>
<b>3:20-3:35</b>	<b>Break</b>	
<b>3:35-3:45</b>	<b>Summary</b>	<b>Alan Bisno</b>

**Breakout sessions:**

- Group 1 Epidemiology; burden of disease
- Group 2 Immunology; Immune correlates; animal models
- Group 3 Vaccine clinical trial design
- Group 4 Implementation